Effects of chlortetracycline and Synovex-S® on growth rate and on plasma growth hormone and thyroid hormone concentrations following administration of thyrotropin-releasing hormone and GH-releasing hormone in beef steers

2007 ◽  
Vol 87 (3) ◽  
pp. 327-341
Author(s):  
S. E. Kitts ◽  
J. C. Matthews ◽  
K. K. Schillo ◽  
T. S. Rumsey ◽  
T. H. Elsasser ◽  
...  

Twenty-four Angus steers (365 kg ± 4) were assigned randomly to a 2 × 2 factorial arrangement of treatments of either 0 or 350 mg chlortetracycline d-1, with or without Synovex-S to test the effects of chlortetracycline (CTC) and estrogenic implant on release of growth hormone (GH) and thyroid hormones. Steers received ad libitum a concentrate-forage diet over a 112-d feeding study, and growth and carcass characteristics were determined. On days 30, 56, and 106, steers received an injection, via jugular catheter, of 1.0 µg kg-1 BW thyrotropin-releasing hormone (TRH) + 0.1 µg kg-1 BW GH-releasing hormone (GHRH) and blood was collected from -30 to 360 min post-injection. Overall, compared with non-implanted steers, Synovex-S increased (P ≤ 0.009) rate and efficiency of gain, decreased (P = 0.05) time to peak for GH concentrations, whereas baseline concentrations of thyroid-stimulating hormone (TSH) were increased (P = 0.03). Additionally, the TSH response curve (P ≤ 0.05) and magnitude of triiodothyronine (T3; P = 0.01) response were greater following TRH + GHRH challenge for implanted versus nonimplanted steers. There were no main effects of CTC; however, CTC attenuated (P ≤ 0.05) the effects of implant on T3 release, slaughter weight, and carcass composition. In conclusion, Synovex-S alone increased BW gain and enhanced the response of GH, TSH, and T3 to a TRH + GHRH challenge, whereas CTC alone did not affect rate and composition of gain or release of pituitary and thyroid hormones. However, CTC appeared to mitigate the effects of implant on T3 release and carcass composition. Key words: Growth hormone, thyroid, estrogen, chlortetracycline, bovine, growth






1981 ◽  
Vol 10 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Mark S. Gold ◽  
A. L. C. Pottash ◽  
David M. Martin ◽  
Lawrence B. Finn ◽  
Robert K. Davies

Ten female patients who satisfied objective criteria for the diagnosis of anorexia nervosa were given 500 ug of thyrotropin releasing hormone. Thyroid stimulating hormone and growth hormone responses were measured in duplicate by radioimmunoassay. These patients had a low normal Δ thyroid stimulating hormone but a delayed peak response. In addition, these patients had pathological growth hormone release in response to thyrotropin releasing hormone infusion. Both delayed peak thyroid stimulating hormone and growth hormone response to thyrotropin releasing hormone have been reported for patients with hypothalamic disorders.



2004 ◽  
Vol 52 (4) ◽  
pp. 389-402 ◽  
Author(s):  
P. Van As ◽  
C. Careghi ◽  
V. Bruggeman ◽  
O. M. Onagbesan ◽  
S. Van der Geyten ◽  
...  

Pit-1 is a pituitary-specific POU-domain DNA binding factor, which binds to and trans-activates promoters of growth hormone- (GH), prolactin- (PRL) and thyroid stimulating hormone beta- (TSHβ) encoding genes. Pit-1 has been identified in several mammalian and avian species. Thyrotropin-releasing hormone (TRH) is located in the hypothalamus and it stimulates TSH, GH and PRL release from the pituitary gland. In the present study, we successfully developed a competitive RT-PCR for the detection of Pit-1 expression in the chicken pituitary, that was sensitive enough to detect picogram levels of Pit-1 mRNA. Applying this method, the effect of TRH injections on Pit-1 mRNA expression was determined in the pituitary of chick embryos and growing chicks. In both 18-day-old embryos and 10-day-old male chicks the Pit-1 mRNA expression was significantly increased following TRH injection, thereby indicating that the stimulatory effects of TRH on several pituitary hormones is mediated via its effect on Pit-1 expression. Therefore, a semi-quantitative RT-PCR method was used to detect possible changes in GH levels. TRH affected the GH mRNA levels at both developmental stages. These results, combined with the data on Pit-1 mRNA expression, indicate that Pit-1 has a role in mediating the stimulatory effects of TRH on pituitary hormones like GH.



1984 ◽  
Vol 14 (4) ◽  
pp. 759-765 ◽  
Author(s):  
S. P. Calloway ◽  
R. J. Dolan ◽  
P. Fonagy ◽  
V. F. A. De Souza ◽  
A. Wakeling

SynopsisThirty-one (43%) of 68 patients with primary depression were found to have a blunted thyroid-stimulating hormone (TSH) response to thyrotropin-releasing hormone (TRH). Increased thyroid activity, as measured by the free thyroxine index (FTI), was present in 16 (24%) of the patients. Patients with blunted responses had a higher mean FTI level than those with normal responses. Patients with blunted responses were significantly more likely to exhibit the symptoms of depersonalization, derealization and agitation. There was no clear association between blunting and any particular diagnostic category of depression.Patients with blunted responses and high FTI values were more likely to report significant long-term environmental difficulties than patients with blunted responses and normal FTI values. It is suggested that there may be more than one mechanism responsible for blunting of the TSH response in depressed patients. In some patients blunting may be due to negative feedback from increased output of thyroid hormones, possibly released as part of a stress response. In other patients blunting may be due to a different mechanism, possibly involving pituitary gland dysfunction. These mechanisms would not necessarily be mutually exclusive in any one patient.









Sign in / Sign up

Export Citation Format

Share Document